Effectiveness of influenza vaccination programme in preventing hospital admissions, Valencia, 2014/15 early results

Eurosurveillance

Volumn 20, Issue 8, 2015, Pages

  Puig Barbera J ^a,b   Mira Iglesias, Ainara ^o   Tortajada Girbés, Miguel ^c   Lopez Labrador F X ^a,d,o   Belenguer Varea, A ^e   Carballido Fernandez M ^f   Carbonell Franco, E ^g   Carratalá Munuera, Concha ^h   Limón Ramírez, Ramón ^j   Mollar Maseres, Joan ^k   Otero Reigada, Maria Del Carmen ^k   Schwarz Chavarri, G ^l   Tuells, J ^m   Gil Guillén, Vicente ⁿ   Javier Diez Domingo, ^o   Natividad Sancho, Angels ^o   Buigues Vila, Amparo ^o   Escribano López, Begoña ^o  

^a Vaccine Research Fundación para el Fomento de la Investigación Sanitaria   (Spain)

^b Centro de Salud Publica de Castellon   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^e HOSPITAL DE LA RIBERA   (Spain)

^f HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^g HOSPITAL ARNAU DE VILANOVA   (Spain)

^h HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

ⁱ MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^j HOSPITAL DE LA PLANA   (Spain)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^m Hospital Universitario del Vinalopo   (Spain)

ⁿ Elda University General Hospital   (Spain)

^o Gerencia FISABIO   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ARTICLE; FEMALE; HEALTH CARE; HOSPITAL ADMISSION; HUMAN; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROGRAM EFFECTIVENESS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPAIN; THROAT CULTURE; ADOLESCENT; CLASSIFICATION; HOSPITALIZATION; IMMUNOLOGY; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; PREVENTIVE HEALTH SERVICE; PROGRAM EVALUATION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VACCINATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROGRAM EVALUATION; RISK FACTORS; VACCINATION; YOUNG ADULT;

EID: 84926676291     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2015.20.8.21044     Document Type: Article

References (21)

1. World Health Organization (WHO). Influenza Update N° 230. 9 February 2015, based on data up to 25 January 2015. Geneva: WHO; 9 February 2015. Available from: http://www.who.int/ influenza/surveillance:monitoring/updates/2015_02_09_ surveillance:update_230.pdf?ua=1
2. Skowronski D, Chambers C, Sabaiduc S, De Serres G, Dickinson J, Winter A, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada s Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4):21022. http://dx.doi.org/10.2807/1560-7917.ES2015.20.4.21022 PMID:25655053
3. McNeil S, Andrew M, Ye L, Haguinet F, Hatchette T, ElSherif M, et al.; Investigators of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN). Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network, January 2015. Euro Surveill. 2015;20(5):21024. http://dx.doi. org/10.2807/1560-7917.ES2015.20.5.21024 PMID:25677052
4. Pebody R, Warburton F, Ellis J, Andrews N, Thompson C, von Wissmann B, et al. Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill. 2015;20(5):21025. http://dx.doi. org/10.2807/1560-7917.ES2015.20.5.21025 PMID:25677050
5. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al. Early estimates of seasonal influenza vaccine effectiveness - United States, january 2015. MMWR Morb Mortal Wkly Rep. 2015;64(1):10-5. PMID:25590680
6. Puig-Barberà J, García-de-Lomas J, Díez-Domingo J, Arnedo- Pena A, Ruiz-García M, Limón-Ramírez R, et al.; Valencia Hospital Network for the Study of Influenza and Respiratory Virus Disease. Influenza vaccine effectiveness in preventing influenza A(H3N2)-related hospitalizations in adults targeted for vaccination by type of vaccine: a hospital-based test-negative study, 2011-2012 A(H3N2) predominant influenza season, Valencia, Spain. PLoS ONE. 2014;9(11):e112294. http://dx.doi.org/10.1371/journal.pone.0112294 PMID:25392931
7. La gripe. [Influenza]. Madrid: Ministerio de Sanidad. [Accessed 25 Feb 2015]. Spanish. Available from: https://www.msssi. gob.es/ciudadanos/enfLesiones/enfTransmisibles/gripe/gripe. htm#Prev1
8. European Influenza Surveillance Network (EISN). Influenza case definitions. Clinical criteria. Influenza-like illness (ILI). Stockholm: European Centre for Disease Prevention and Control (ECDC). [Accessed: 2 Nov 2012]. Available from: http://ecdc.europa.eu/en/activities/surveillance/EISN/surveillance/ Pages/influenza_case_definitions.aspx
9. World Health Organization (WHO). WHO information for molecular diagnosis of influenza virus in humans - update. Geneva: WHO; November 2012. Available from: http://www. who.int/influenza/gisrs_laboratory/molecular_diagnosis_ influenza_virus_humans_update_201211.pdf
10. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013;31(17):2165-8. http://dx.doi.org/10.1016/j.vaccine.2013.02.053 PMID:23499601
11. Sullivan SG, Feng S, Cowling BJ. Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. Expert Rev Vaccines. 2014;13(12):1571-91. http://dx.doi.org/10.1586/14760584.2014.966695 PMID:25348015
12. Ellis PD. The essential guide to effect sizes: statistical power, meta-analysis, and the interpretation of research results. Cambridge; New York: Cambridge University Press; 2010.
13. Pearl J. Causal diagrams for empirical research. Biometrika. 1995;82(4):669-88. http://dx.doi.org/10.1093/ biomet/82.4.669
14. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10(1):37-48. http://dx.doi.org/10.1097/00001648-199901000-00008 PMID:9888278
15. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 1974;66(5):688-701. http://dx.doi.org/10.1037/h0037350
16. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656-64. http://dx.doi.org/10.1093/aje/kwn164 PMID:18682488
17. Informe semanal de vigilancia de la gripe en España. Semana 06/2015. [Weekly surveillance report on influenza in Spain. Week 06/2015]. No 422. Madrid: Instituto de Salud Carlos III; 12 Feb 2015. Spanish. Available from: http://www.isciii. es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-enfermedades/fd-gripe/grn062015.pdf
18. Jefferson TO, Rivetti D, Di Pietrantonj C, Rivetti A, Demicheli V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007; (2):CD001269. PMID:17443504
19. Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Med. 2013;11(1):153. http://dx.doi.org/10.1186/1741-7015-11-153 PMID:23800265
20. Kelly HA, Sullivan SG, Grant KA, Fielding JE. Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64 years, 2007-2011. Influenza Other Respi Viruses. 2013;7(5):729-37. http://dx.doi.org/10.1111/irv.12018 PMID:23078073
21. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36-44. http://dx.doi.org/10.1016/S1473-3099(11)70295-X PMID:22032844